United-Guardian Q3 revenue rises on Renacidin sales, net income jumps

Overview

• US life sciences and personal care supplier's Q3 revenue rose 54% yr/yr, net income up 247%

• Growth driven by higher pharmaceutical, cosmetic ingredient, and medical lubricant sales

• Expanded formulary coverage for Renacidin contributed to pharmaceutical sales growth

Outlook

• Company plans new marketing efforts to boost awareness of Renacidin among healthcare professionals

• United-Guardian expects to launch a new personal care product early next yr

Result Drivers

• RENACIDIN SALES - Pharmaceutical sales rose 29% yr/yr, mainly due to increased Renacidin sales after expanded formulary coverage

• COSMETIC INGREDIENTS - Cosmetic ingredient sales jumped 187% yr/yr, led by higher purchases from Ashland Specialty Ingredients

• MEDICAL LUBRICANTS - Medical lubricant sales increased 20% yr/yr, driven by higher orders from a customer in India

Company press release:

Key Details

Reuters Recommended Reads

• Nov 9 - Ionis Pharmaceuticals Q3 revenue rises 55%

• Nov 9 - Israel's Kamada Q3 revenue up 11%, raises forecast

• Nov 9 - ImmunityBio Q3 revenue rises on Anktiva sales growth but misses estimates

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)